MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-06-2025
Rezolute Retained Earnings 2011-2025 | RZLT
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings Rezolute
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -404 M | -329 M | -261 M | -209 M | -168 M | -147 M | -127 M | -94.2 M | -64.3 M | -44 M | -29.1 M | -17.7 M | -8.02 M | -91.2 K | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -91.2 K | -404 M | -136 M |
Quarterly Retained Earnings Rezolute
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -422 M | -404 M | -379 M | -361 M | -345 M | -329 M | -306 M | -289 M | -276 M | -261 M | -248 M | -233 M | -219 M | -209 M | -200 M | -189 M | -176 M | -168 M | -168 M | -158 M | -151 M | -147 M | -147 M | -139 M | -132 M | -127 M | -127 M | -102 M | -97.5 M | -94.2 M | -94.2 M | -76.7 M | -71 M | -64.3 M | -64.3 M | -52.7 M | -47.9 M | -44 M | -44 M | -36.5 M | -32.4 M | -29.1 M | -29.1 M | -22.9 M | -17.7 M | -17.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -17.7 M | -422 M | -160 M |
Retained Earnings of other stocks in the Biotechnology industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AbbVie
ABBV
|
-7.9 B | $ 223.01 | -0.99 % | $ 395 B |  USA |
 |
ARCA biopharma
ABIO
|
-83.7 M | - | 1052.0 % | $ 415 M | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
-1.28 B | $ 4.68 | 1.85 % | $ 777 M |  Canada |
 |
Aclaris Therapeutics
ACRS
|
-903 M | $ 3.38 | 3.21 % | $ 261 M | USA |
 |
Acasti Pharma
ACST
|
-221 M | - | 4.01 % | $ 150 M | Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
-1.02 B | - | -15.15 % | $ 60.3 M |  Britain |
 |
Aeglea BioTherapeutics
AGLE
|
-972 M | - | - | $ 1.01 B | USA |
 |
Ascendis Pharma A/S
ASND
|
-611 M | $ 212.3 | 5.5 % | $ 5 B |  Danmark |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.24 B | - | - | $ 40.3 B | USA |
 |
BioVie
BIVI
|
-352 M | $ 1.54 | -2.53 % | $ 2.28 M | USA |
 |
Albireo Pharma
ALBO
|
-301 M | - | -0.23 % | $ 916 M | USA |
 |
Aptorum Group Limited
APM
|
-72.4 M | $ 1.33 | -1.48 % | $ 7.25 M |  China |
 |
Alpine Immune Sciences
ALPN
|
-224 M | - | - | $ 2.17 B | USA |
 |
Alterity Therapeutics Limited
ATHE
|
-182 M | $ 3.4 | 1.49 % | $ 8.18 B |  Australia |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-108 M | - | -1.52 % | $ 24.7 M | USA |
 |
AstraZeneca PLC
AZN
|
5.3 B | $ 90.34 | -1.28 % | $ 96.9 B | Britain |
 |
Amphastar Pharmaceuticals
AMPH
|
569 M | $ 25.76 | 0.19 % | $ 1.25 B | USA |
 |
Anika Therapeutics
ANIK
|
128 M | $ 9.53 | -1.19 % | $ 140 M | USA |
 |
Aytu BioScience
AYTU
|
-334 M | $ 2.33 | 2.3 % | $ 14.6 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
-2.12 B | - | -6.81 % | $ 3.04 B | USA |
 |
Avenue Therapeutics
ATXI
|
-103 M | - | -52.27 % | $ 4.45 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
69.4 M | - | - | - |  Russia |
 |
Axon Enterprise
AXON
|
812 M | $ 586.28 | 3.15 % | $ 44.4 B | USA |
 |
Biogen
BIIB
|
19.3 B | $ 173.03 | -2.55 % | $ 25.2 B | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-166 M | $ 0.29 | -5.01 % | $ 631 M |  Israel |
 |
Brickell Biotech
BBI
|
-172 M | - | -5.38 % | $ 6.06 M | USA |
 |
Benitec Biopharma
BNTC
|
-228 M | $ 12.91 | 0.78 % | $ 531 M | USA |
 |
BioNTech SE
BNTX
|
-410 M | $ 95.9 | 0.17 % | $ 27.2 B |  Germany |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
-2.59 B | $ 11.55 | 8.86 % | $ 747 M | USA |
 |
Enochian Biosciences
ENOB
|
-510 M | - | - | $ 40.5 M | USA |
 |
Catalyst Biosciences
CBIO
|
-85.5 M | $ 15.32 | 5.73 % | $ 1.01 B | USA |
 |
Acer Therapeutics
ACER
|
-141 M | - | 2.71 % | $ 14 M | USA |
 |
BeiGene, Ltd.
BGNE
|
-8.61 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Cerus Corporation
CERS
|
-1.07 B | $ 2.14 | 13.23 % | $ 395 M | USA |
 |
Acorda Therapeutics
ACOR
|
-1.19 B | - | -24.86 % | $ 820 K | USA |
|
Applied Molecular Transport
AMTI
|
-366 M | - | - | $ 10.1 M | USA |
 |
Berkeley Lights
BLI
|
-362 M | - | -7.31 % | $ 87 M | USA |
 |
bluebird bio
BLUE
|
-4.26 B | - | - | $ 546 M | USA |
 |
Cellectar Biosciences
CLRB
|
-203 M | $ 3.81 | -5.35 % | $ 46.6 M | USA |
 |
Bristol-Myers Squibb Company
BMY
|
14.9 B | $ 51.05 | -0.32 % | $ 103 B | USA |
 |
Abeona Therapeutics
ABEO
|
-750 M | $ 5.5 | 0.46 % | $ 118 M | USA |
 |
ADiTx Therapeutics
ADTX
|
-168 M | $ 2.36 | -7.29 % | $ 31.1 K | USA |
 |
BioXcel Therapeutics
BTAI
|
-650 M | $ 2.1 | -4.34 % | $ 5.32 M | USA |
 |
Coherus BioSciences
CHRS
|
-1.58 B | $ 1.42 | 6.77 % | $ 134 M | USA |
 |
BioLineRx Ltd.
BLRX
|
-278 M | $ 3.22 | -2.72 % | $ 908 M | Israel |
 |
Celldex Therapeutics
CLDX
|
-1.56 B | $ 28.33 | 0.5 % | $ 1.82 M | USA |
 |
Advaxis
ADXS
|
-197 M | - | -9.65 % | $ 45.9 M | USA |
 |
Baudax Bio
BXRX
|
-191 M | - | 0.59 % | $ 63 K | USA |
 |
Завод ДИОД
DIOD
|
1.21 B | - | - | - | Russia |